Saga Yasushi, Suzuki Mitsuaki, Mizukami Hiroaki, Urabe Masashi, Fukushima Masakuza, Ozawa Keiya, Sato Ikuo
Department of Obstetrics and Gynecology and Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan.
Oncology. 2002;63(2):185-91. doi: 10.1159/000063804.
It has been shown that there is an inverse relationship between the level of thymidylate synthase (TS) and therapeutic outcomes in patients with malignancies including cervical cancer. To clarify the mechanism of the poor prognosis of cervical cancer with high TS expression, we introduced TS cDNA to the human uterine cervical cancer cell line SKG-II and evaluated the effect of TS expression on its radiosensitivity. After selection, stable transformants of SKG-II cells expressing high level of TS (SKG-II/TS) and control cells (SKG-II/luciferase) were obtained. The level of TS measured by the FdUMP-TS binding assay was significantly higher (p < 0.05) in SKG-II/TS than in control (2.0 +/- 0.1 and 1.3 +/- 0.1 pmol/mg, respectively). No difference was observed in in vitro cell growth or in vivo tumor growth. On evaluation of in vitro radiosensitivity, the 50% growth inhibitory dose (ID(50)) was 3.1 +/- 0.1 Gy in SKG-II/TS and was significantly higher (p < 0.01) than that in control (2.2 +/- 0.1 Gy). From these results, it is suggested that one of the reasons of poor outcome of cervical cancer to radiation is high TS expression.
研究表明,在包括宫颈癌在内的恶性肿瘤患者中,胸苷酸合成酶(TS)水平与治疗效果呈负相关。为阐明TS高表达的宫颈癌预后不良的机制,我们将TS cDNA导入人子宫颈癌细胞系SKG-II,并评估TS表达对其放射敏感性的影响。经过筛选,获得了高表达TS的SKG-II细胞稳定转化株(SKG-II/TS)和对照细胞(SKG-II/荧光素酶)。通过FdUMP-TS结合试验测定的TS水平在SKG-II/TS中显著高于对照(分别为2.0±0.1和1.3±0.1 pmol/mg,p<0.05)。在体外细胞生长或体内肿瘤生长方面未观察到差异。在评估体外放射敏感性时,SKG-II/TS的50%生长抑制剂量(ID50)为3.1±0.1 Gy,显著高于对照(2.2±0.1 Gy,p<0.01)。从这些结果来看,提示宫颈癌放疗效果不佳的原因之一是TS高表达。